NO20081713L - Pyrimidinderivater og deres anvendelse som KCNQ-kaliumkanalapnere - Google Patents

Pyrimidinderivater og deres anvendelse som KCNQ-kaliumkanalapnere

Info

Publication number
NO20081713L
NO20081713L NO20081713A NO20081713A NO20081713L NO 20081713 L NO20081713 L NO 20081713L NO 20081713 A NO20081713 A NO 20081713A NO 20081713 A NO20081713 A NO 20081713A NO 20081713 L NO20081713 L NO 20081713L
Authority
NO
Norway
Prior art keywords
pyrimidine derivatives
potassium channel
channel openers
kcnq potassium
openers
Prior art date
Application number
NO20081713A
Other languages
English (en)
Norwegian (no)
Inventor
Mario Rottlander
Daniel Rodriguez Greve
Nikolay Khanzhin
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20081713L publication Critical patent/NO20081713L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20081713A 2005-09-09 2008-04-09 Pyrimidinderivater og deres anvendelse som KCNQ-kaliumkanalapnere NO20081713L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200501262 2005-09-09
PCT/DK2006/050039 WO2007065449A1 (fr) 2005-09-09 2006-09-07 Derives de pyrimidine et leur emploi en tant qu'agents ouvrant les canaux potassiques kcnq

Publications (1)

Publication Number Publication Date
NO20081713L true NO20081713L (no) 2008-06-04

Family

ID=37199174

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081713A NO20081713L (no) 2005-09-09 2008-04-09 Pyrimidinderivater og deres anvendelse som KCNQ-kaliumkanalapnere

Country Status (15)

Country Link
EP (1) EP1937653A1 (fr)
JP (1) JP2009507052A (fr)
KR (1) KR20080043314A (fr)
CN (1) CN101258133A (fr)
AR (1) AR055420A1 (fr)
AU (1) AU2006322461A1 (fr)
BR (1) BRPI0615631A2 (fr)
CA (1) CA2621854A1 (fr)
EA (1) EA200800780A1 (fr)
IL (1) IL189545A0 (fr)
MX (1) MX2008002294A (fr)
NO (1) NO20081713L (fr)
UA (1) UA93387C2 (fr)
WO (1) WO2007065449A1 (fr)
ZA (1) ZA200802174B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201070189A1 (ru) * 2007-08-01 2010-08-30 Х. Лундбекк А/С Применение соединений, открывающих калиевые каналы kcnq, для подавления симптомов или лечения расстройств или состояний, при которых нарушается дофаминергическая система
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
WO2010097379A1 (fr) * 2009-02-24 2010-09-02 Neurosearch A/S Dérivés pyrimidine substitués et leur utilisation médicale
JP5763758B2 (ja) * 2010-07-08 2015-08-12 ファイザー・インク Ｋｖ７カリウムチャネル開口薬としてのピペリジニルピリミジンアミド
EP3318556A1 (fr) * 2010-10-20 2018-05-09 Grünenthal GmbH 6-amino-nicotinamides substitués en tant que modulateurs kcnq2/3
CN103508943B (zh) * 2012-06-29 2017-06-09 江苏先声药业有限公司 作为钾通道调节剂的化合物
CN103508960B (zh) * 2012-06-29 2017-12-12 江苏先声药业有限公司 苯并杂环衍生物
KR20170076673A (ko) * 2014-10-24 2017-07-04 오노 야꾸힝 고교 가부시키가이샤 Kcnq2∼5 채널 활성화제
WO2021023616A1 (fr) * 2019-08-02 2021-02-11 H. Lundbeck A/S Dérivés d'alcool en tant qu'agents d'ouverture des canaux potassiques kv7 à utiliser dans l'épilepsie ou les crises d'épilepsie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1361879A1 (fr) * 2001-02-20 2003-11-19 Bristol-Myers Squibb Company Derives de 2,4-disubstitue pyrimidine-5-carboxamide en tant que modulateur des canaux potassium kcnq
AU2003202115A1 (en) * 2002-02-12 2003-09-04 Pfizer Inc. Non-peptide compounds affecting the action of gonadotropin-releasing hormone (gnrh)
US20080261918A1 (en) * 2004-12-17 2008-10-23 Graham Andrew Showell Silicon Compounds and Their Use

Also Published As

Publication number Publication date
ZA200802174B (en) 2009-10-28
AR055420A1 (es) 2007-08-22
IL189545A0 (en) 2008-06-05
BRPI0615631A2 (pt) 2011-05-24
EP1937653A1 (fr) 2008-07-02
AU2006322461A1 (en) 2007-06-14
WO2007065449A1 (fr) 2007-06-14
MX2008002294A (es) 2008-03-14
JP2009507052A (ja) 2009-02-19
CN101258133A (zh) 2008-09-03
EA200800780A1 (ru) 2008-06-30
CA2621854A1 (fr) 2007-06-14
UA93387C2 (ru) 2011-02-10
KR20080043314A (ko) 2008-05-16

Similar Documents

Publication Publication Date Title
NO20081713L (no) Pyrimidinderivater og deres anvendelse som KCNQ-kaliumkanalapnere
NO20071843L (no) Substituerte anilinderivater
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20074959L (no) Substituerte pyridinderivater
SG164368A1 (en) Treatment of cancer
NO20091509L (no) Substituerte tetrahydropyrrolopyrazinforbindelser med affinitet KCNQ2/3 K+ kanal og anvendelse derav i medikamenter
WO2007027238A3 (fr) Inhibiteurs de kinase jak et utilisations de ceux-ci
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
MX2009006195A (es) Compuestos basados en 4-fenil-6-(2,2,2-trifluoro-1-feniletoxi)piri midina y metodos de su uso.
MX2009011210A (es) Inhibidores de mcl1 de indol 7-no sustituido.
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
GEP20094785B (en) Pyrrolopyrazoles, potent kinase inhibitors
NO20071549L (no) Nye benzofuserte heteroalrylsulfamidderivater, anvendelige som anti-krampemidler
NO20066055L (no) Pyridinderivater
NO20076054L (no) Imidiazo - og triazolopyridiner som inhibitorer av 11-beta-hydroksysteroid-dehydrogenase type I
NO20081454L (no) Met-kinaseinhibitorer
NO20073068L (no) Stereoisomere anrikete 3-aminokarbonylbisykloheptenpyrimidindiaminforindelser og deres anvendelse
TN2009000128A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
WO2005110994A3 (fr) Derives de pyrazolyl uree substitues utiles dans le traitement du cancer
WO2007092622A3 (fr) Compositions et méthodes pour le traitement d'os
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
PL1937669T3 (pl) Nowe pochodne benzopiranu jako „otwieracze" kanału potasowego
NO20054371L (no) Somatostatin-dopamin kimaere analoger
IL190730A0 (en) Potassium channel inhibitors

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

FC2A Withdrawal, rejection or dismissal of laid open patent application